DrugPatentWatch Database Preview
APADAZ Drug Profile
When do Apadaz patents expire, and what generic alternatives are available?
Apadaz is a drug marketed by Kempharm and is included in one NDA. There are five patents protecting this drug.
This drug has twenty-seven patent family members in nineteen countries.
The generic ingredient in APADAZ is acetaminophen; benzhydrocodone hydrochloride. There are sixty-six drug master file entries for this compound. Additional details are available on the acetaminophen; benzhydrocodone hydrochloride profile page.
Summary for APADAZ
| International Patents: | 27 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | APADAZ at DailyMed |
Generic Entry Opportunity Date for APADAZ
Generic Entry Date for APADAZ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for APADAZ
International Patents for APADAZ
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 20120048589 | ➤ Try a Free Trial |
| World Intellectual Property Organization (WIPO) | 2011002991 | ➤ Try a Free Trial |
| Japan | 5442862 | ➤ Try a Free Trial |
| Russian Federation | 2012103476 | ➤ Try a Free Trial |
| Australia | 2010266205 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
